Search
Erlotinib
go.drugbank.com/drugs/DB00530ApprovedInvestigationalErlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer … This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloproliferative disorders.
Tea tree oil
go.drugbank.com/drugs/DB11218ApprovedNutraceuticalTea tree oil is an essential oil derived mainly from the Australian native plant _Melaleuca alternifolia_ via steam distillation of the of the leaves and terminal branches [A32439]. … It has been a popular ingredient in a variety of household and cosmetic products due to its antiseptic, anti-inflammatory, broad-spectrum antimicrobial and antioxidant properties [A32438].
Synonyms: Snow-in-summer leaf oilCategories: Complex MixturesRomiplostim
go.drugbank.com/drugs/DB05332ApprovedInvestigationalRomiplostim is produced by recombinant DNA technology in Escherichia coli. FDA approved on August 22, 2008. … Each subunit consists of an IgG1 Fc carrier domain that is covalently attached to a polypeptide sequence that contains two binding domains to interact with thrombopoietin receptor c-Mpl.
Pyrazinamide
go.drugbank.com/drugs/DB00339ApprovedInvestigationalA pyrazine that is used therapeutically as an antitubercular agent.
Diclofenamide
go.drugbank.com/drugs/DB01144ApprovedA carbonic anhydrase inhibitor that is used in the treatment of glaucoma.
Butamben
go.drugbank.com/drugs/DB11148ApprovedWithdrawnButamben is a local anesthetic in the form of n-butyl-p-aminobenzoate. … [A27147] Its structure corresponds to the standard molecule of a hydrophilic and hydrophobic domain separated by an intermediate ester found in most of the local anesthetics.
Ganaxolone
go.drugbank.com/drugs/DB05087ApprovedInvestigational[L41135] In July 2023, ganaxolone was also approved under the same brand name and for the same indication by the EMA.[L47636] … [L41130] It was approved under the brand name ZTALMY by the US FDA in March 2022 for the treatment of seizures associated with CDKL5 deficiency disorder (CDD), becoming the first FDA-approved treatment
Mecasermin rinfabate
go.drugbank.com/drugs/DB14751ApprovedInvestigationalIn 2007 Insmed withdrew their application for a marketing authorization with The European Medicines Agency[F4075]. … Mecasermin rinfabate manufactured by Insmed Incorporated under the brand name Iplex was approved by the FDA in 2005[L5722].
Ripretinib
go.drugbank.com/drugs/DB14840ApprovedInvestigationalRipretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA on May 15, 2020. … [L13769] It is the first drug approved as a fourth-line therapy in the specific setting of prior treatment with a minimum of 3 other kinase inhibitors.[L13778]
Doxacurium
go.drugbank.com/drugs/DB01135ApprovedWithdrawnDoxacurium chloride is a long-acting, nondepolarizing skeletal muscle relaxant for intravenous administration.